Henry M. Jackson Foundation for the Advancement of Military Medicine
The purpose of this research is to evaluate the overall use of the WounDx medical device in a clinical setting, such as a hospital. The WounDx device is experimental and not yet approved by the United States Food and Drug Administration (FDA). WounDx uses information about a patient's wound to generate a report that a surgeon may use to help determine when to close or not close the wound. The final decision to close the wound remains with the surgeon. The results from this pilot trial will inform a larger pivotal trial.
Determining if a large, traumatic extremity wound is ready for successful delayed closure remains a challenge, as approximately 23%-25% of these wounds fail to heal after delayed closure is attempted, even when treated with aggressive open wound care procedures, including surgical debridement or operative washout every 2-3 days. This pilot trial uses WounDx, a device that aids clinicians in identifying extremity wounds that are likely to heal after surgical closure. The device is a Clinical Decision Support Tool (CDST) and consists of two main components: an immunoassay to obtain the expressio…
Inclusion Criteria: Traumatic or surgically created (e.g., fasciotomy) wounds that meet the following criteria: * Wound surface area ≥60 cm² * Extremity injury (including shoulder and buttock - without visceral communication) * Wound amenable to Negative Pressure Wound Therapy using 3M™ V.A.C.® canisters without gel pack * Age ≥18 to ≤75 years Exclusion Criteria: * Insulin Dependent Diabetes * Peripheral Vascular Disease * Connective Tissue Disorders * Preexisting immunosuppressive conditions or immunosuppression therapy * Pregnancy * Prisoners
WounDx is a clinical decision support tool that combines an immunoassay of six inflammatory biomarkers measured in wound effluent with wound characteristics to estimate the probability of successful wound closure. A probability of 0.85 or greater indicates a recommendation to close the wound at the next wound care procedure occurring 48-96 hours after the previous procedure. WounDx is applicable up to 21 days post-injury and augments the clinicians' judgment; the final closure decision remains with the clinician.
The standard of care consists of negative pressure wound therapy and serial wound care procedures, including wound irrigation, surgical debridement, operative washout, and NPWT dressing changes.